The nel-like1 (NELL1) gene maps to chromosome 11p15, which frequently undergoes loss of heterozygosity in esophageal adenocarcinoma (EAC). NELL1 promoter hypermethylation was examined by real-time methylationspecific polymerase chain reaction in 259 human esophageal tissues. Hypermethylation of this promoter showed highly discriminative receiver-operator characteristic curve profiles, clearly distinguishing esophageal squamous cell carcinoma (ESCC) and EAC from normal esophagus (NE) (Po0.001). NELL1 normalized methylation values were significantly higher in Barrett's metaplasia (BE), dysplastic Barrett's (D) and EAC than in NE (Po0.0000001). NELL1 hypermethylation frequency was zero in NE but increased early during neoplastic progression, to 41.7% in BE from patients with Barrett's alone, 52.5% in D and 47.8% in EAC. There was a significant correlation between NELL1 hypermethylation and BE segment length. Three (11.5%) of 26 ESCCs exhibited NELL1 hypermethylation. Survival correlated inversely with NELL1 hypermethylation in patients with stages I-II (P ¼ 0.0264) but not in stages III-IV (P ¼ 0.68) EAC. Treatment of KYSE220 ESCC and BIC EAC cells with 5-aza-2 0 -deoxycytidine reduced NELL1 methylation and increased NELL1 mRNA expression. NELL1 mRNA levels in EACs with an unmethylated NELL1 promoter were significantly higher than those in EACs with a methylated promoter (P ¼ 0.02). Promoter hypermethylation of NELL1 is a common, tissue-specific event in human EAC, occurs early during Barrett's-associated esophageal neoplastic progression, and is a potential biomarker of poor prognosis in early-stage EAC.
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Introduction
Esophageal cancer ranks sixth among all cancers worldwide, with 400 000 new cases being diagnosed per year (Stewart and Kleihues, 2003) . This malignancy exists in two principal forms, each possessing distinct pathological characteristics: esophageal squamous cell carcinoma (ESCC), which occurs at high frequencies in many developing countries, particularly in Asia, and esophageal adenocarcinoma (EAC), which is more prevalent in Western countries, with a rapid rate of increase in recent years (Stewart and Kleihues, 2003) . Although significant advances have been made in the treatment of esophageal cancers, these aggressive malignancies commonly present as locally advanced disease with a very poor prognosis (approximately 14% 5-year survival) (Jemal et al., 2005) . Therefore, it is important to discover novel early detection biomarkers and targets for future chemoprevention or therapy.
The Nel (strongly expressed in neural tissues and containing epidermal growth factor (EGF)-like domains) gene, encoding a protein containing six EGFlike domains, was first cloned from a chick embryoderived cDNA library in 1995 (Matsuhashi et al., 1995 (Matsuhashi et al., , 1996 . Later, Watanabe et al. (1996) cloned a human Nel gene designated nel-like type1 (NELL1) from a human fetal-brain cDNA library in 1996. The NELL1 gene has been mapped to chromosome 11p15 (Watanabe et al., 1996) , a locus that frequently shows loss of heterozygosity (LOH) in human cancers, including EAC (Dolan et al., 1998) . LOH is one mechanism of gene inactivation, but other mechanisms exist, including point mutation, allelic or homozygous deletion, and promoter hypermethylation (Knudson, 2001) . It is now well established that promoter hypermethylation correlates with silencing of gene transcription in cancers (Herman and Baylin, 2003) , including ESCC and EAC (Fang et al., 2005; Schulmann et al., 2005) . Recently, data from our laboratory showed that the NELL1 promoter was hypermethylated in 15 (44%) of 34 human colon cancers, and that the demethylating agent 5-aza-2 0 -deoxycytidine (5-Aza-dC) reversed NELL1 promoter hypermethylation and restored NELL1 mRNA expression in colon cancer cell lines (Mori et al., 2006) . There is a growing body of evidence showing that the abnormal methylation of DNA is an early event in carcinogenesis and can serve as an early detection biomarker in some cancers (Herman and Baylin, 2003) . Based on these findings, we hypothesized that NELL1 might be inactivated via promoter hypermethylation in human esophageal cancers, and that hypermethylation of NELL1 could occur early in the genesis of EAC, while simultaneously constituting a potentially useful early detection biomarker in this disease.
To test this hypothesis, we studied methylation of the NELL1 gene promoter by real-time quantitative methylation-specific polymerase chain reaction (PCR) (qMSP) in 259 endoscopic esophageal biopsy specimens of differing histologies. The effect of a DNA methyltransferase inhibitor, 5-Aza-dC, on the re-expression of epigenetically silenced NELL1 was also studied in esophageal cancer cell lines. Our results show that promoter hypermethylation of NELL1 is a common event in EAC but uncommon in ESCC, occurs early during Barrett's-associated esophageal neoplastic progression, and is associated with a poor prognosis in early-stage EAC patients.
Results

NELL1 promoter hypermethylation in different esophageal tissues
Promoter hypermethylation of NELL1 was analysed in 66 normal esophagi (NE), 60 Barrett's metaplasias without dysplasia (BE, including 36 BEs from patients with Barrett's alone (Ba) and 24 BEs obtained from patients with Barrett's accompanied by EAC (Bt)), 19 low-grade (LGD) and 21 high-grade (HGD) dysplasias occurring within BE, 67 EACs, and 26 ESCCs. All assays were performed in duplicate format, and data showed reproducible and concordant results. NELL1 promoter hypermethylation showed highly discriminative receiver-operator characteristic (ROC) curve profiles, clearly distinguishing both ESCC (Po0.001) and EAC (Po0.0001) from NE, as well as EAC from ESCC (Po0.0001). ROC curves with corresponding areas under the ROC curve (AUROCs) for NELL1 of EAC vs NE, ESCC vs NE, combined esophageal cancer (T) vs NE and EAC vs ESCC are shown in Figure 1 .
The cutoff normalized methylation value (NMV) for NELL1 (0.1) was chosen from the ROC curve in order to maximize sensitivity and specificity. Mean NMVs and NELL1 hypermethylation frequencies for each tissue type are shown in Figure 2b ). Three (11.5%) of 26 ESCCs showed hypermethylation of NELL1. There was no significant difference between ESCC and NE in NELL1 NMVs for 13 cases with matched ESCC (mean ¼ 0.0295) and NE (mean ¼ 0.006; P ¼ 0.2, Student's paired t-test; Figure 2c ). Both NELL1 hypermethylation frequency and mean NMV were significantly higher in EAC than in ESCC (47.8% vs 11.5%; P ¼ 0.0016 and 0.1527 vs 0.0233; P ¼ 0.0015, respectively), as well as in D vs ESCC (52.5% vs 11.5%; P ¼ 0.0007 and 0.183 vs 0.0233; P ¼ 0.0007, respectively), and in BE vs ESCC (46.7% vs 11.5%; P ¼ 0.0016 and 0.1846 vs 0.0233; P ¼ 0.0003; summarized in Table 1 ).
Survival curves were analysed according to UICC classifications (International Union against Cancer, 2002) . Overall patient survival correlated with NELL1 methylation status in stages I-II EAC patients, but not in stages III-IV EAC patients ( Figure 3 ). Stages I-II EAC patients with NELL1 hypermethylation had significantly shorter survivals than did patients without NELL1 hypermethylation (mean 25.7 months vs 45.4 months; P ¼ 0.0264, Log-rank test; Figure 3a ). There was no statistically significant difference between NELL1 hypermethylation and overall survival in stages III-IV EAC patients (P ¼ 0.6827, Log-rank test; Figure 3b ).
BE was defined as long-segment (LSBE) if it was equal to or greater than 3 cm in length, or short-segment (SSBE) if less than 3 cm, according to generally accepted criteria (Rudolph et al., 2000) . The mean NMV of NELL1 was significantly higher in LSBE (mean ¼ 0.2948) than in SSBE (mean ¼ 0.0654; P ¼ 0.0061, Student's t-test, Figure 4a ). Similarly, segment lengths of BEs with hypermethylated NELL1 promoters (mean ¼ 5.86 cm) were significantly greater than segment lengths of BEs with unmethylated NELL1 promoters (mean ¼ 2.81 cm; P ¼ 0.0098, Student's t-test; Figure 4b ), and the frequency of NELL1 hypermethylation was significantly higher in LSBE than in SSBE (P ¼ 0.0061, Fisher's exact test; Table 2 ).
No significant associations were observed between NELL1 promoter hypermethylation and patient age (data not shown), tumor stage or lymph node metastasis (Table 3) , smoking or alcohol drinking status (Table 3) , or degree of histologic differentiation in EACs (Table 1) .
NELL1 methylation and mRNA levels in esophageal cancer cell lines after 5-Aza-dC treatment Seven (78%) of nine ESCC and two (67%) of three EAC cell lines showed high NELL1 NMV levels above the Hypermethylation of NELL1 in esophageal cancer Z Jin et al cutoff level of 0.1 (Figure 5a ). Cell lines BIC and KYSE 220, which exhibited some of the highest NMVs between the EAC and ESCC cell lines, respectively, were subjected to 5-Aza-dC treatment. After 5-Aza-dC treatment, the NMV of NELL1 was diminished in both BIC EAC cells and KYSE220 ESCC cells, while the mRNA level of NELL1 showed a dramatic increase in BIC cells, but only a trend toward increasing in KYSE220 cells (Figure 5b and c).
Correlation between hypermethylation and mRNA expression of NELL1 gene in EACs To further elucidate the relationship between DNA hypermethylation and mRNA expression of NELL1, we determined NELL1 mRNA levels in 22 EAC samples using quantitative real-time reverse transcription (RT)-PCR (qRT-PCR). NELL1 mRNA levels in EACs with unmethylated NELL1 were significantly higher than those in EACs with hypermethylated NELL1 (P ¼ 0.02, Mann-Whitney U-test; Figure 6 ).
Discussion
The NELL1 gene encodes a protein kinase C-binding protein that contains six EGF-like domains and belongs to a new class of cell-signaling molecules controlling cell growth and differentiation (Matsuhashi et al., 1995; Watanabe et al., 1996; Kuroda and Tanizawa, 1999; Desai et al., 2006 ). The precise roles of NELL1 in Hypermethylation of NELL1 in esophageal cancer Z Jin et al physiology and pathophysiology remain incompletely elucidated. Overexpression of NELL1 increased osteoblast differentiation and reduced cell proliferation in transgenic mice, while downregulation of NELL1 using in vitro approaches demonstrated inhibited osteoblast differentiation and suggested that decreased levels of NELL1 protein lead to promoted cell proliferation at the suture line (Zhang et al., 2002) . It has also been reported that overexpression of NELL1 promotes apoptosis in osteoblasts both in vitro and in vivo (Zhang et al., 2003) , and that this apoptotic activity may be associated with the Fas signaling pathway (Zhang et al., 2006) . In NELL1 6R mutant mice, loss of NELL1 expression was associated with reduced expression of genes encoding tumor necrosis factor receptor superfamily member 11b and extracellular matrix proteins (Desai et al., 2006) , which have also been implicated in human carcinogenesis (Ingber, 2002; Rowinsky, 2005) . Furthermore, the high frequency (44%) of NELL1 promoter hypermethylation in colon cancer suggests a potential role for NELL1 inactivation in colon tumorigenesis (Mori et al., 2006) . The NELL1 chromosomal locus reveals a high frequency of LOH or allelic imbalance in human cancers, including EAC (Dolan et al., 1998; Gleeson et al., 1998) . Taken together, these findings suggest that NELL1 functions as a tumor suppressor gene in certain human cancers.
In the current study, we systematically investigated hypermethylation of the NELL1 gene promoter in primary human esophageal lesions of differing histological types and neoplastic stages, as well as in esophageal carcinoma cell lines. Our results demonstrate that hypermethylation of NELL1 occurs early in some subjects, that the frequency of this epigenetic event increases early during EAC carcinogenesis, and that this event is common in human EACs, but uncommon in ESCCs. Thus, NELL1 hypermethylation appears to be a critical and unique event in human EAC, rather than in ESCC. However, four of 15 cases with corresponding NE, BE and EAC were hypermethylated only in BE, but There is increasing evidence that promoter hypermethylation has prognostic value in cancer patients, including those with esophageal cancer (Kawakami et al., 2000; Brock et al., 2003; Lee et al., 2006) . Brock et al. (2003) demonstrated that hypermethylation of multiple genes was a powerful predictor of poor prognosis in EAC patients. Lee et al. (2006) reported that the Fragile Histidine Triad gene was methylated in 85 (33%) of 257 ESCCs and associated with a poor prognosis for stages 1-2 cases. Furthermore, our previous work showed that methylation of Adenomatous Polyposis Coli gene DNA could be detected in plasma and was associated with a poor prognosis in EAC patients (Kawakami et al., 2000) . In the current study, hypermethylation of NELL1 was significantly associated with shortened survival in stages I-II EAC patients. Thus, hypermethylation of NELL1 may constitute a useful biomarker of biologically aggressive disease in early-stage EAC patients.
Conflicting results have been reported from different studies regarding the length of Barrett's esophagus as a predictive factor for BE progression. While several previous studies stated that patients with SSBE may develop dysplasia (Sharma et al., 1997) and EAC (Rudolph et al., 2000) , some prospective studies have shown an increased risk of EAC development only in patients with LSBE (Weston et al., 1997; Hirota et al., 1999; Hage et al., 2004) . Rudolph et al. (2000) demonstrated that segment length was not related to cancer risk in a prospective cohort study of 309 Barrett's patients followed in the Seattle Barrett's Esophagus Project (P>0.2); however, when patients with HGD at entrance were excluded, a strong trend was observed, with a 5 cm difference in length associated with a 1.7-fold increase in cancer risk (95% confidence interval, 0.8-to 3.8-fold). Weston et al. (1997) reported significant differences between SSBE and LSBE in the frequency of both dysplasia and EAC, at 8.1 vs 24.4% for dysplasia (Po0.0001) and 0 vs 15.4% for EAC (Po0.0005). Hirota et al. (1999) reported that the prevalence of dysplasia and cancer differed significantly in patients with SSBE vs patients with LSBE in a comprehensive prospective study of 889 consecutive patients. More recently, Hage et al. (2004) reported a significantly increased risk of progression to HGD or EAC with LSBE after a mean follow-up of 12.7 years. Thus, it is likely that length of Barrett's epithelium is an important risk factor for both the prevalence of concurrent dysplasia and cancer and the incidence of future malignant progression. Interestingly, NELL1 hypermethylation showed a strong relationship to BE segment length in the current study. Therefore, NELL1 methylation may constitute both a molecular correlate of BE segment length and a potential biomarker for the prediction of BE progression.
In this study, hypermethylation of NELL1 in BIC and KYSE220 cell lines was associated with silenced or reduced expression of NELL1 mRNA. As expected, treatment of these cells with 5-Aza-dC led to concomitant increases in mRNA expression and reductions in NELL1 methylation levels. This restoration of NELL1 mRNA expression by demethylating agent treatment is consistent with the hypothesis that DNA hypermethylation was responsible for silencing of NELL1. The involvement of CpG island hypermethylation in silencing of the NELL1 gene is also supported by the current study's finding that NELL1 mRNA levels in primary EACs with unmethylated NELL1 promoters were significantly higher than those in EACs with hypermethylated NELL1 promoters (P ¼ 0.02). Furthermore, 5-Aza-dC or its derivatives have shown potential as therapeutic anticancer drugs (Lemaire et al., 2005; Momparler, 2005) , and thus NELL1 represents a novel potential target for molecular-based EAC therapies involving demethylation.
The current study indicates that hypermethylation of the NELL1 promoter, which leads to gene silencing, is a common event in human EACs, occurs early in Barrett's-associated esophageal adenocarcinogenesis, and is associated with a poor prognosis in early-stage EAC patients. In addition, NELL1 hypermethylation is uncommon in human ESCC, appearing to represent a cell type-specific biomarker for EAC as opposed to ESCC. Further large-scale prospective longitudinal validation studies of this biomarker as a predictor of outcome in HGD or early EAC are justified by these data. These results also provide a stimulus for further research into potential applications of selected DNA methyltransferase or other indirect methylation inhibitors in the prevention or treatment of esophageal cancer.
Materials and methods
Tissue samples
In the current study, 66 NEs, 60 BEs (36 Ba and 24 Bt), 40 Ds (19 LGD and 21 HGD), 67 EACs and 26 ESCCs were examined. All patients provided written informed consent under a protocol approved by the Institutional Review Boards at the University of Maryland School of Medicine, the Baltimore Veterans Affairs Medical Center, and the Johns Hopkins University School of Medicine. Biopsies were taken using a standardized biopsy protocol as described previously (Schulmann et al., 2005) . Research tissues were obtained from grossly apparent normal esophageal mucosa, Barrett's epithelium or mass lesions in patients manifesting these changes at endoscopic examination, and histology was confirmed using parallel aliquots obtained at endoscopy. There was no histological evidence of esophagitis for NE. All normal esophageal tissues in this study were unmatched, and only seven (10.4%) of 67 EAC patients received preoperative chemotherapy and/or radiotherapy. Outcome data were derived from a comprehensive database maintained by the institution's cancer registry and patients' medical records at the University of Maryland and Baltimore Veterans Affairs Medical Centers. All biopsy specimens were stored in liquid nitrogen until DNA extraction. Clinicopathologic characteristics of patients are summarized in Table 1 .
Cell lines
Three EAC (BIC, OE33 and SEG) and nine ESCC (KYSE 110, 140, 180, 200, 220, 410, 450, 520 and 850) cell lines were obtained from collaborators at the University of Michigan (Dr David Beer) and Kyoto University (Professor Yutaka Shimada). These cells were cultured in 47.5% Roswell Park Memorial Institute 1640 medium, 47.5% F-12 supplemented with 5% fetal bovine serum.
DNA and RNA extraction Genomic DNA was extracted from biopsies and cultured cells using a DNeasy Tissue Kit (Qiagen, Valencia, CA, USA). Total RNA was isolated from biopsies and cultured cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). DNAs and RNAs were stored at À801C before analysis.
Bisulfite treatment and real-time methylation-specific PCR DNA was treated with bisulfite to convert unmethylated cytosines to uracils before qMSP, as described previously (Mori et al., 2006) . Promoter methylation levels of NELL1 were determined by qMSP with the ABI 7700 Sequence Detection (Taqman, Applied Biosystems, Foster City, CA, USA) System, using primers and probes as described previously (Mori et al., 2006) . NMV was defined as follows: NMV ¼ (NELL1-S/NELL1-FM)/(ACTB-S/ACTB-FM), where NELL1-S and NELL1-FM represent NELL1 methylation levels in sample and fully methylated DNAs, respectively, while ACTB-S and ACTB-FM correspond to b-actin in sample and fully methylated DNAs, respectively.
Real-time quantitative RT-PCR
To determine NELL1 mRNA levels, one-step qRT-PCR was performed using a Qiagen QuantiTect Probe RT-PCR Kit (Qiagen, Hilden, Germany) and the ABI 7700 Sequence Detection (Taqman, Applied Biosystems) System. Primers and probes were the same as reported previously (Mori et al., 2006) . b-Actin was used for normalization of data. A standard curve was generated using serial dilutions of qPCR Reference Total RNA (Clontech, Mountain View, CA, USA). Normalized mRNA value (NRV) was calculated according to the following formula for relative expression of target mRNA: NRV ¼ (TarS/TarC)/(ACTB-S/ACTB-C), where TarS and TarC represent levels of mRNA expression for the target gene in sample and control mRNAs, respectively, whereas ACTB-S and ACTB-C correspond to amplified b-actin levels in sample and control mRNAs, respectively.
5-Aza-dC treatment of esophageal cancer cell lines
To determine whether NELL1 inactivation was due to promoter hypermethylation in esophageal cancer, two esophageal cancer cell lines (KYSE220 and BIC) were subjected to 5-Aza-dC (Sigma, St Louis, MO, USA) treatment as described previously (Bender et al., 1999; Shibata et al., 2002) . Briefly, 1 Â 10 5 cells/ml were seeded onto a 100 mm dish and grown for 24 h. Then, 1 ml of 5 mM 5-Aza-dC per ml of cells was added every 24 h for 6 days. DNAs and RNAs were harvested on day 6. Data analysis and statistics ROC curve analysis (Hanley and McNeil, 1982) was performed using NMVs for the 67 EAC, 26 ESCC and 66 NE by Analyse-it software (Version 1.71; Analyse-it Software, Leeds, UK). Using this approach, the AUROC identitifed optimal sensitivity and specificity levels (i.e., cutoffs) at which to distinguish normal from malignant esophageal tissues, and corresponding NMV thresholds were calculated for NELL1. The cutoff value determined from this ROC curve was applied to determine the frequency of NELL1 methylation in each tissue type included in the present study. For all other tests, Statistica (version 6.1; StatSoft Inc., Tulsa, OK, USA) was used. Differences with Po0.05 were deemed significant.
